GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$43.44 USD
-0.47 (-1.07%)
Updated Sep 3, 2024 04:00 PM ET
Pre-Market: $43.47 +0.03 (0.07%) 9:26 AM ET
3-Hold of 5 3
A Value C Growth C Momentum B VGM
Price, Consensus and EPS Surprise
GSK 43.44 -0.47(-1.07%)
Will GSK be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for GSK based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GSK
3 Top Dividend Stocks to Maximize Your Retirement Income
Why Is Glaxo (GSK) Up 10.3% Since Last Earnings Report?
GSK: What are Zacks experts saying now?
Zacks Private Portfolio Services
GSK's RSV Vaccine Arexvy Gets EU Nod for Adults Aged 50-59 Years
GSK Stock Gains 18.5% Year to Date: Time to Buy, Sell or Hold?
Gilead (GILD) Gains 16.8% in 3 Months: How Should You Play the Stock?
Other News for GSK
Innoviva's Rollercoaster: Critical Care Bets With Respiratory Backing
Deutsche Bank Reaffirms Their Buy Rating on GlaxoSmithKline (GSK)
Amid Major Threats, Merck Stock Is A Sell
Gilead Sciences: Buy This Bargain Before It's Gone
European Commission approves expanded age indication for GSK's Arexvy